Concepts (134)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 18 | 2026 | 1290 | 3.420 |
Why?
|
| Glucokinase | 6 | 2023 | 61 | 1.880 |
Why?
|
| Genetic Testing | 8 | 2023 | 606 | 1.740 |
Why?
|
| Diabetes Mellitus, Type 1 | 6 | 2026 | 686 | 1.590 |
Why?
|
| Insulin Infusion Systems | 2 | 2021 | 59 | 1.240 |
Why?
|
| Pancreas, Artificial | 2 | 2021 | 41 | 1.240 |
Why?
|
| Diabetes Mellitus | 10 | 2026 | 813 | 1.090 |
Why?
|
| Pregnancy in Diabetics | 2 | 2018 | 44 | 1.080 |
Why?
|
| Insulin | 6 | 2021 | 1224 | 1.050 |
Why?
|
| Hypoglycemic Agents | 7 | 2025 | 416 | 0.990 |
Why?
|
| Blood Glucose | 4 | 2026 | 914 | 0.720 |
Why?
|
| Precision Medicine | 6 | 2026 | 502 | 0.690 |
Why?
|
| Self-Management | 1 | 2021 | 50 | 0.660 |
Why?
|
| Mutation | 12 | 2026 | 4428 | 0.640 |
Why?
|
| Diabetic Ketoacidosis | 3 | 2026 | 15 | 0.550 |
Why?
|
| Patient Participation | 1 | 2020 | 250 | 0.540 |
Why?
|
| Sulfonylurea Compounds | 7 | 2025 | 75 | 0.530 |
Why?
|
| Registries | 8 | 2026 | 1128 | 0.520 |
Why?
|
| Pregnancy Outcome | 1 | 2018 | 284 | 0.490 |
Why?
|
| Child | 14 | 2026 | 7750 | 0.480 |
Why?
|
| Cost-Benefit Analysis | 3 | 2019 | 525 | 0.470 |
Why?
|
| Adolescent | 14 | 2026 | 10140 | 0.450 |
Why?
|
| Adolescent Behavior | 1 | 2015 | 118 | 0.410 |
Why?
|
| Medication Adherence | 1 | 2015 | 130 | 0.410 |
Why?
|
| Mass Screening | 1 | 2019 | 751 | 0.400 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 5 | 2017 | 123 | 0.390 |
Why?
|
| Models, Theoretical | 2 | 2019 | 509 | 0.350 |
Why?
|
| Infant, Newborn | 9 | 2026 | 2551 | 0.320 |
Why?
|
| Humans | 33 | 2026 | 98370 | 0.320 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2021 | 75 | 0.320 |
Why?
|
| Sleep | 2 | 2025 | 465 | 0.310 |
Why?
|
| Female | 22 | 2026 | 51761 | 0.280 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2019 | 168 | 0.270 |
Why?
|
| Hyperglycemia | 2 | 2019 | 187 | 0.260 |
Why?
|
| Young Adult | 8 | 2026 | 7568 | 0.260 |
Why?
|
| Male | 21 | 2026 | 47263 | 0.260 |
Why?
|
| Genomics | 1 | 2013 | 903 | 0.250 |
Why?
|
| Child, Preschool | 7 | 2026 | 4042 | 0.250 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2026 | 11 | 0.240 |
Why?
|
| Deafness | 1 | 2026 | 50 | 0.230 |
Why?
|
| Mitochondrial Diseases | 1 | 2026 | 16 | 0.230 |
Why?
|
| Pancreatic Diseases | 1 | 2026 | 61 | 0.230 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 3 | 2023 | 81 | 0.230 |
Why?
|
| Adult | 13 | 2026 | 29587 | 0.220 |
Why?
|
| Gastric Inhibitory Polypeptide | 1 | 2025 | 12 | 0.220 |
Why?
|
| Biomarkers | 3 | 2025 | 2021 | 0.220 |
Why?
|
| Weight Gain | 1 | 2026 | 138 | 0.220 |
Why?
|
| Pancreas | 1 | 2026 | 269 | 0.210 |
Why?
|
| Sleep Wake Disorders | 1 | 2025 | 139 | 0.200 |
Why?
|
| Sleep Disorders, Intrinsic | 1 | 2023 | 5 | 0.190 |
Why?
|
| Infant | 6 | 2026 | 3361 | 0.190 |
Why?
|
| Heart Rate | 1 | 2026 | 534 | 0.190 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 2 | 2013 | 32 | 0.190 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2026 | 229 | 0.190 |
Why?
|
| United States | 5 | 2021 | 8262 | 0.180 |
Why?
|
| Pedigree | 2 | 2026 | 987 | 0.180 |
Why?
|
| Life Expectancy | 2 | 2019 | 93 | 0.180 |
Why?
|
| Pregnancy | 2 | 2018 | 3269 | 0.160 |
Why?
|
| Computer Literacy | 1 | 2020 | 3 | 0.160 |
Why?
|
| Attitude to Computers | 1 | 2020 | 11 | 0.160 |
Why?
|
| Monitoring, Ambulatory | 1 | 2020 | 32 | 0.160 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 165 | 0.160 |
Why?
|
| Diffusion of Innovation | 1 | 2020 | 81 | 0.150 |
Why?
|
| Biomedical Research | 1 | 2025 | 471 | 0.150 |
Why?
|
| Health Care Surveys | 1 | 2020 | 282 | 0.150 |
Why?
|
| Hyperinsulinism | 1 | 2019 | 44 | 0.150 |
Why?
|
| Prevalence | 2 | 2024 | 1393 | 0.140 |
Why?
|
| Genetic Markers | 1 | 2019 | 471 | 0.140 |
Why?
|
| Birth Weight | 1 | 2018 | 150 | 0.140 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 161 | 0.140 |
Why?
|
| Hepatocyte Nuclear Factors | 1 | 2018 | 2 | 0.140 |
Why?
|
| Siblings | 2 | 2016 | 113 | 0.140 |
Why?
|
| Abortion, Spontaneous | 1 | 2018 | 74 | 0.130 |
Why?
|
| Health Care Costs | 1 | 2019 | 259 | 0.130 |
Why?
|
| Treatment Outcome | 3 | 2020 | 9770 | 0.130 |
Why?
|
| Hypoglycemia | 1 | 2017 | 114 | 0.120 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 513 | 0.120 |
Why?
|
| Middle Aged | 9 | 2026 | 29532 | 0.120 |
Why?
|
| Insulin Resistance | 1 | 2019 | 391 | 0.120 |
Why?
|
| Trans-Activators | 2 | 2026 | 447 | 0.120 |
Why?
|
| Potassium Channels | 1 | 2018 | 352 | 0.110 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 1785 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 602 | 0.110 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2016 | 94 | 0.110 |
Why?
|
| Homeodomain Proteins | 2 | 2026 | 568 | 0.110 |
Why?
|
| Delayed Diagnosis | 1 | 2015 | 41 | 0.110 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 686 | 0.110 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 578 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2016 | 1570 | 0.100 |
Why?
|
| Developmental Disabilities | 1 | 2016 | 217 | 0.100 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 2056 | 0.090 |
Why?
|
| Internet | 1 | 2011 | 359 | 0.070 |
Why?
|
| RNA, Transfer, Leu | 1 | 2026 | 14 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2013 | 3228 | 0.060 |
Why?
|
| GATA4 Transcription Factor | 1 | 2026 | 21 | 0.060 |
Why?
|
| Incidence | 2 | 2026 | 1787 | 0.060 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2026 | 56 | 0.060 |
Why?
|
| DNA, Mitochondrial | 1 | 2026 | 211 | 0.060 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2025 | 65 | 0.050 |
Why?
|
| Sulfonylurea Receptors | 2 | 2014 | 50 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2025 | 765 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2025 | 867 | 0.040 |
Why?
|
| Family | 1 | 2023 | 329 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2023 | 481 | 0.040 |
Why?
|
| Insulin-Secreting Cells | 1 | 2024 | 453 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2024 | 11043 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2025 | 4044 | 0.030 |
Why?
|
| Cost Savings | 1 | 2017 | 68 | 0.030 |
Why?
|
| Markov Chains | 1 | 2017 | 147 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2017 | 194 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2017 | 139 | 0.030 |
Why?
|
| Prognosis | 1 | 2025 | 4126 | 0.030 |
Why?
|
| Neurologic Manifestations | 1 | 2016 | 10 | 0.030 |
Why?
|
| Selection Bias | 1 | 2016 | 38 | 0.030 |
Why?
|
| Glyburide | 1 | 2015 | 34 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2016 | 335 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2016 | 309 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 369 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2016 | 567 | 0.030 |
Why?
|
| Risk Factors | 1 | 2023 | 6273 | 0.020 |
Why?
|
| Receptors, Drug | 1 | 2011 | 51 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2016 | 2009 | 0.020 |
Why?
|
| Epidemiologic Research Design | 1 | 2011 | 23 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2011 | 145 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1947 | 0.020 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2011 | 105 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 1974 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 2667 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2010 | 375 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 1296 | 0.020 |
Why?
|
| Aged | 2 | 2017 | 21844 | 0.020 |
Why?
|
| Chicago | 1 | 2011 | 1519 | 0.020 |
Why?
|
| Algorithms | 1 | 2011 | 2003 | 0.010 |
Why?
|
| Animals | 1 | 2010 | 28981 | 0.000 |
Why?
|